Levicept

About:

Levicept develops biological agent for the treatment of chronic pain.

Website: http://www.levicept.com/

Twitter/X: levicept

Top Investors: Innovate UK, Index Ventures, Advent Life Sciences, Gilde Healthcare

Description:

With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability. Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. We are progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis.

Total Funding Amount:

12.4M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Sandwich, Kent, United Kingdom

Founded Date:

2012-01-01

Contact Email:

info(AT)levicept.com

Founders:

Simon Westbrook

Number of Employees:

1-10

Last Funding Date:

2014-10-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai